Edition:
India

Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C


Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Ardelyx Inc ::ARDELYX SUCCESSFULLY COMPLETES T3MPO-3 SAFETY EXTENSION STUDY OF TENAPANOR FOR IBS-C.ARDELYX - ‍RESULTS FROM BOTH T3MPO-1 AND T3MPO-2 STUDIES, SAFETY DATA, SUPPORT CO'S PLANS TO SUBMIT FIRST NDA TO U.S. FDA FOR THE INDICATION IN H2 2018​.ARDELYX INC - RESULTS FROM T3MPO-3 SHOWED THAT TENAPANOR WAS WELL-TOLERATED AMONG 240 PATIENTS TREATED. 

Company Quote

6.02
0.0 +0.00%
11 Nov 2019